Global Tauopathies Market Analysis 2017 - Key Trends, Innovative Products, Market Segments, and Companies
PUNE, India, Aug. 4, 2017 /PRNewswire-iReach/ -- Global Tauopathies Market Analysis 2017 - Key Trends, Innovative Products, Market segments, and Companies report states that once the first drug in the tauopathies market is approved, it could incentivize R&D from other pharma companies, setting an example for an effective therapeutic approach and regulatory approval process. Additionally, the approval of a drug in one tauopathy indication is likely to prompt its off-label use in other indications, driving sales further.Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive Supranuclear palsy (PSP), CorticoBasal Degeneration (CBD), frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), Pick?s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition, apathy), cognitive (e.g. memory loss), language (e.g. slurring of speech), or motor (e.g. falls, tremor) deficits.
View more on this research report at http://www.reportsnreports.com/reports/933299-pharmafocus-tauopathies-global-market-analysis.html
According to Akiko Fukui, Healthcare Analyst, there are currently no approved therapies to treat tauopathy patients, and as such, the first-to-market drug will secure a high patient share, boosting sales and establishing a strong company presence in the tauopathies space. In turn, the market will be made more attractive for other manufacturers, as strong sales performance of the first product will reduce financial risk. Moreover, the possibility of expanding sales from the tauopathies market into the much larger Alzheimer's disease space is another strong incentive for drug manufacturers, as successful entry into these markets would provide huge revenue.
Report helps to develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list, business strategies by understanding the trends shaping and driving the global tauopathy therapeutics market, drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global tauopathy therapeutics market in future, formulate effective sales and marketing strategies by understanding the competitive landscape and identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Purchase this 196 pages report at http://www.reportsnreports.com/purchase.aspx?name=933299
About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Media Contact: Ritesh Tiwari, ReportsnReports, +1-888-391-5441, sales@reportsnreports.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports
